Navigation Links
Pharmacyclics Reports Second Quarter 2014 Results
Date:7/31/2014

The enrollment target of this global study is 400 patients.

Marginal Zone Lymphoma (MZL)

  • PCYC-1121: Phase II study of IMBRUVICA in patients with R/R marginal zone lymphoma was initiated in the fourth quarter of 2013. This is a multi center, open-label, monotherapy study to evaluate the safety and efficacy of IMBRUVICA in patients with R/R marginal zone lymphoma. The primary endpoint of this study is overall response rate and the enrollment target of this study is 60 patients.
  • Waldenstrom's Macroglobulinemia (WM)

  • PCYC-1127: Phase III study of IMBRUVICA or placebo in combination with rituximab in patients with previously treated WM was initiated in the second quarter of 2014. This is a randomized, multi-center, double-blinded, placebo-controlled trial of IMBRUVICA.  The primary outcome measure of this study is PFS. The secondary outcome measures include ORR, time to next treatment, OS and number of participants with AEs as a measure of safety and tolerability within each treatment arm. The enrollment target of this study is 180 patients.
  • Multiple Myeloma (MM)

  • PCYC-1111: Phase II study of IMBRUVICA in patients with R/R multiple myeloma was initiated in the first quarter of 2012. This is a Phase II, multi-center, open-label trial designed to assess the safety and efficacy of IMBRUVICA as a single agent and in combination with dexamethasone in patients with R/R MM. At this time, an expansion of cohorts 1, 2 and 3 (420mg, 560mg with dexamethasone, and 840mg) is not planned due to the fact that the protocol-defined response rate was not achieved. The Company has expanded the fourth and final dosing cohort to 43 patients (840mg with dexamethasone) as it crossed a minimum pre-defined boundary of efficacy. The clinical development focus of IMBRUVICA in this indication will be in combination therapies.
  • PCYC-1119: Phase I/IIb study of IMBRUVICA in combination with carfilzomib in patients wi
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

    Related medicine technology :

    1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
    2. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
    3. WuXi PharmaTech to Partner with Pharmacyclics
    4. Pharmacyclics Reports Third Quarter 2013 Results
    5. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
    6. Pharmacyclics Reports Second Quarter 2013 Results
    7. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    8. Pharmacyclics Reports First Quarter 2013 Results
    9. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    10. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    11. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/29/2015)... Eli Lilly and Company (NYSE: LLY ... Healthcare Conference on Tuesday, June 9, 2015. Jeffrey ... Health, will participate in a fireside chat at 2:20 ... audio webcast will be available on the "Webcasts & ... . A replay of the fireside chat will be ...
    (Date:5/29/2015)... Va. , May 29, 2015 LifeNet ... its total hiring for 2015 to more than 160 ... by increased demand for LifeNet Health,s innovative bio-implants, which ... allowing more patients to be served. It also is ... biomedical industry. "The growth and success of ...
    (Date:5/29/2015)... Mass. , May 29, 2015  Haemonetics Corporation ... Davies , Chief Operating Officer, will present at the ... York on June 23 rd , 2015 ... may access Mr. Davies, presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
    Breaking Medicine Technology:Lilly to Participate in Goldman Sachs Global Healthcare Conference 2LifeNet Health to add more than 160 jobs in 2015 2
    ... Medical Devices strengthened its executive team with the appointment ... Joseph Lee, Xeridiem Medical Devices, President said, "I am ... Medical Devices as Vice-President Business Development, effective March 1, ... design and development services with a focus on sales ...
    ... N.J., March 7, 2011 Ajinomoto Co., a ... and safe, effective nutraceutical solutions, has announced that ... granted federal trademark registration, (®), on the Principal ... Office.  The trademark is the latest milestone for ...
    Cached Medicine Technology:Xeridiem Medical Devices Appoints Renae Moomjian, Vice President, Business Development 2Ajinomoto Co.'s Capsiate Natura® Reaches New Milestone 2
    (Date:5/29/2015)... (PRWEB) May 29, 2015 Red Hot ... the newest Red Hot & Blue restaurant at 525 New ... Thursday, May 7, 2015. “The Red Hot & Blue Restaurant ... 18 years, but we have moved to a new location ... in the middle of all the activities on the Promenade–with ...
    (Date:5/29/2015)... RIDGELAND, Miss. (PRWEB) May 29, 2015 ... recently announced the graduates of its Advanced Training ... trains students, who fill roles in their health ... both the theory and methodology of continuous quality ... is a sister-program to Dr. Brent James’ internationally ...
    (Date:5/29/2015)... Inspire Nexus, a new social network officially launching ... many life coaches have asked, "How do I find ... to become a credentialed Coach?" , Many Life and ... long. Inspire Nexus, a social network for Coaches provides ... have experience coaching a certain number of hours, qualify ...
    (Date:5/29/2015)... 29, 2015 The campaign focuses on ... a number of specific concerns within, including the importance ... mental health in the workplace. We are encouraged to ... campaign also brings special focus to people living with ... up and seek help from healthcare professionals and their ...
    (Date:5/29/2015)... 2015 The report “Muscle Spasm ... on the therapeutic development for Muscle Spasm. Spasms ... the body, leading to many different symptoms and ... new targets and MOAs to produce first-in-class and ... review of Axillary Hyperhidrosis with 19 market data ...
    Breaking Medicine News(10 mins):Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 3Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 4Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:Mediaplanet Brings Activism to Those Living with Mental Illness in Bew “Mental Health Awareness” Campaign 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
    ... parity insurance less likely to get timely outpatient care , , ... better share the burden of the cost for mental health ... up less of the bill, a new study says. , ... some of whose plans provided equal cost-sharing and others whose ...
    ... Clinical pharmacy services can significantly reduce the cost of ... care system, according to a new study by researchers ... every dollar spent by hospitals or health systems to ... drug costs, reductions in adverse drug events and medication ...
    ... , , TUESDAY, Dec. 23 (HealthDay News) -- As many ... States combine over-the-counter medications with prescription drugs in ways ... a new survey finds. , A recent report estimated ... emergency department visits for adverse drug reactions each year, ...
    ... and Human Services recently awarded Jefferson Hospital for Neuroscience ... organ donation conversion rate of 75 percent or greater ... given during the fourth National Learning Congress held in ... and staff at Jefferson Hospital for Neuroscience work tirelessly ...
    ... virtually a micro-camera, is a revolutionary diagnostic tool in diagnosing small ... GI tract, though the number of the images for the lesions ... reader still has to scan ten thousands of the images one ... lesions are in. So, it may be a big burden on ...
    ... of radiation therapy to treat cancer inevitably involves exposure ... have been well established, a number of patients experience ... These side effects related to inflammatory process cause discomfort ... treatment time. , A research article to be ...
    Cached Medicine News:Health News:Psych Patients With Cost-Sharing Plans Use More Services 2Health News:Drug Combinations Putting Seniors at Risk 2Health News:Drug Combinations Putting Seniors at Risk 3Health News:Drug Combinations Putting Seniors at Risk 4Health News:Jefferson Hospital for Neuroscience receives Department of Health and Human Services award 2Health News:What is the mechanism of the chronic radiation enteritis? 2
    The Oxoid Legionella Latex Test is a latex agglutination test for the identification of predominant Legionella species grown on plate media from patients with suspected Legionellosis or from environm...
    ... A revolutionary new agar plate for economically screening ... this biplate with the urine specimen. If the ... the chromogenic side of the biplate will 3 ... E. coli, the BluEcoli™ Urine Biplate is a ...
    ... The Trinity Biotech Captia™ Legionella ... (ELISA) is intended for the ... (IgG and IgM) to Legionella ... serum from patients with clinical ...
    SDA is a patented isothermal amplification technology capable of generating billions of copies of target molecules from a single DNA or RNA template in just minutes....
    Medicine Products: